dm+d
Unassigned
New Medicines
ExblifepUrinary tract infection
Information
Exblifep
New molecular entity
Allecra Therapeutics
Allecra Therapeutics
Development and Regulatory status
None
Phase III Clinical Trials
Phase III Clinical Trials
Category
Cephalosporins, carbapenems and other beta-lactams (05.01.02)
Extended-spectrum β-lactamase inhibitor
The population eligible to receive this difficult to estimate and may vary according to local resistance patterns. In England (2018/19), ~190,000 hospital admissions were for complicated urinary tract infections, including pyelonephritis and sepsis due to gram-negative bacteria. [11]
Urinary tract infection
Serious, hospital acquired, gram-negative multi drug-resistant infections in combination with cefepime (a 4th generation cephalosporin antibiotic)
Intravenous